RT Journal Article
T1 Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.
A1 Martinez-Lopez, Joaquin
A1 Alonso, Rafael
A1 Wong, Sandy W
A1 Rios, Rafael
A1 Shah, Nina
A1 Ruiz-Heredia, Yanira
A1 Sanchez-Pina, Jose Maria
A1 Sanchez, Ricardo
A1 Bahri, Natasha
A1 Zamanillo, Irene
A1 Poza, Maria
A1 Buenache, Natalia
A1 Encinas, Cristina
A1 Juarez, Luis
A1 Miras, Fatima
A1 Collado, Luis
A1 Barrio, Santiago
A1 Martin, Thomas
A1 Cedena, Maria Teresa
A1 Wolf, Jeffrey
K1 Measurable residual disease
K1 Minimal residual disease
K1 Multiple myeloma
AB The assessment of measurable residual disease (MRD) in bone marrow has proven of prognostic relevance in patients with multiple myeloma (MM). Nevertheless, and unlike other hematologic malignancies, the use of MRD results to make clinical decisions in MM has been underexplored to date. In this retrospective study, we present the results from a multinational and multicenter series of 400 patients with MRD monitoring during front-line therapy with the aim of exploring how clinical decisions made based on those MRD results affected outcomes. As expected, achievement of MRD negativity at any point was associated with improved PFS versus persistent MRD positivity (median PFS 104 vs. 45 months, p 
YR 2021
FD 2021-08-17
LK http://hdl.handle.net/10668/18386
UL http://hdl.handle.net/10668/18386
LA en
DS RISalud
RD Apr 10, 2025